These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17306904)

  • 1. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
    Barrios V; Escobar C; Calderón A; Vegazo O; Fernandez R; Asín E
    Diabetes Res Clin Pract; 2007 Sep; 77(3):492-3. PubMed ID: 17306904
    [No Abstract]   [Full Text] [Related]  

  • 2. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
    Iwashima Y; Okada M; Haneda M; Yoshida T
    Diabetes Res Clin Pract; 2006 Oct; 74(1):8-14. PubMed ID: 16720057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients.
    Derosa G; Cicero AF; Mugellini A; Ciccarelli L; Fogari R
    J Hum Hypertens; 2003 Jun; 17(6):433-5. PubMed ID: 12764407
    [No Abstract]   [Full Text] [Related]  

  • 4. Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
    Ogihara T; Fujimoto A; Ueshima K; Nakao K; Saruta T
    J Am Geriatr Soc; 2011 Jan; 59(1):180-1. PubMed ID: 21226700
    [No Abstract]   [Full Text] [Related]  

  • 5. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study.
    Barrios V; Escobar C; Calderón A; Tomás JP; Ruiz S; Moya JL; Megías A; Vegazo O; Fernandez R
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):236-42. PubMed ID: 17318794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan: from left ventricular hypertrophy to heart failure, a global approach.
    Barrios V; Escobar C; Calderon A
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):825-34. PubMed ID: 17867913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan.
    Cuspidi C; Leonetti G; Zanchetti A
    Blood Press Suppl; 2003 Dec; 2():5-15. PubMed ID: 14761071
    [No Abstract]   [Full Text] [Related]  

  • 11. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial.
    Schram MT; van Ittersum FJ; Spoelstra-de Man A; van Dijk RA; Schalkwijk CG; Ijzerman RG; Twisk JW; Stehouwer CD
    J Hum Hypertens; 2005 Jun; 19(6):429-37. PubMed ID: 15647778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.
    Ogihara T; Fujimoto A; Nakao K; Saruta T
    J Am Geriatr Soc; 2010 Feb; 58(2):395-6. PubMed ID: 20370872
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
    Mansour G; Mansour J
    Curr Hypertens Rep; 2002 Dec; 4(6):437-8. PubMed ID: 12419171
    [No Abstract]   [Full Text] [Related]  

  • 15. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan effect on inflammation in hypertension.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Hypertens Res; 2010 Mar; 33(3):209-13. PubMed ID: 20075928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study.
    Kawamori R; Fujita T; Matsuoka H; Umemura S; Saito Y
    Diabetes Res Clin Pract; 2009 Feb; 83(2):241-8. PubMed ID: 19097664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS
    Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
    [No Abstract]   [Full Text] [Related]  

  • 20. Candesartan.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12163443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.